News 2023-06-23
Porton Pharma Solutions Welcomes Dr. Wenfang Miao as CEO of Porton USA, L.L.C. and J-STAR Research, Inc., Ushering in a New Era of Pharmaceutical Innovation
Join us in welcoming Dr. Wenfang Miao (Renee) as the new CEO of Porton USA, L.L.C. and J-STAR Research, Inc., and Vice-President of Porton Pharma Solutions, LTD. Dr. Miao brings with her more than 25 years of experience in technical, operational, and strategic leadership within the pharmaceutical industry as she will navigate Porton’s overall business strategies, operations, and business development and growth in the United States. We are looking forward to Porton’s stronger foothold in pharmaceutical innovation with her leadership. We are rooting for you, Dr. Miao!
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
